Commitment to the pharmaceutical location NRW: WuXi Biologics, a global leader in contract research, development and production for biopharmaceuticals, plans to expand its production capacities in Leverkusen and Wuppertal. The Chinese company is thus responding to the growing global demand for services in the pharmaceutical industry.
The company already fills around ten million doses a year in the 13,000 square meter sterile filling and freeze-drying facility at Chempark Leverkusen. Now WuXi Biologics is planning another filling station of the same size. The company also plans to double the capacity of its bioreactors from 12,000 liters to 24,000 liters in a 30,000-square-meter facility.
Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, emphasizes the importance of the strategic expansion at the two sites for the Group: "By expanding capacity in Germany, WuXi Biologics aims to meet the growing needs of our global customers, especially in Europe, and to be close to our customers. The expansion of the two sites is a clear commitment to Germany and Europe as a high-tech location and to the long-term growth strategy of WuXi Biologics.
